A detailed history of Jane Street Group, LLC transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 287,717 shares of LYEL stock, worth $175,507. This represents 0.0% of its overall portfolio holdings.

Number of Shares
287,717
Previous 175,800 63.66%
Holding current value
$175,507
Previous $254,000 56.3%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.13 - $1.88 $126,466 - $210,403
111,917 Added 63.66%
287,717 $397,000
Q2 2024

Aug 14, 2024

SELL
$1.3 - $3.01 $14,878 - $34,449
-11,445 Reduced 6.11%
175,800 $254,000
Q1 2024

May 15, 2024

SELL
$1.71 - $3.07 $199,769 - $358,649
-116,824 Reduced 38.42%
187,245 $417,000
Q4 2023

Feb 14, 2024

BUY
$1.39 - $2.35 $402,153 - $679,899
289,319 Added 1961.48%
304,069 $589,000
Q3 2023

Nov 14, 2023

SELL
$1.45 - $3.35 $68,618 - $158,532
-47,323 Reduced 76.24%
14,750 $21,000
Q2 2023

Aug 14, 2023

SELL
$1.89 - $3.86 $256,068 - $522,975
-135,486 Reduced 68.58%
62,073 $197,000
Q1 2023

May 15, 2023

BUY
$1.97 - $3.58 $389,191 - $707,261
197,559 New
197,559 $466,000
Q2 2022

Aug 16, 2022

SELL
$3.68 - $6.8 $50,795 - $93,860
-13,803 Reduced 51.37%
13,069 $85,000
Q1 2022

May 17, 2022

SELL
$5.05 - $7.7 $313,408 - $477,869
-62,061 Reduced 69.78%
26,872 $136,000
Q4 2021

Feb 15, 2022

BUY
$7.13 - $15.19 $491,777 - $1.05 Million
68,973 Added 345.56%
88,933 $688,000
Q3 2021

Nov 16, 2021

BUY
$11.0 - $17.95 $219,560 - $358,282
19,960 New
19,960 $295,000

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $151M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.